Protai has built an end-to-end AI-based platform that comprehensively maps the course of disease on the protein level, enhancing the ability to observe cellular function and improve the way new drugs are discovered.
The company's platform uses technology that comprehensively maps the course of a disease on the protein level, unmasking deep cellular function, allowing researchers to unlock complex biological insights in drug development and improve the R&D process while lowering costs.
B2B
1 to 25
Seed
$8 M
Scaling Up
2021
Healthcare
Biotechnology
N/A
N/A
Service
Yes
Active
Machine Learning
N/A
Software
Machine Learning Engineer
Tel Aviv, Tel Aviv
Software Engineer
Tel Aviv, Tel Aviv
Computational Biologist
Tel Aviv, Tel Aviv
Director of Drug Discovery
Tel Aviv, Tel Aviv
AI/ML Professionals
2
2
$10M
Company was founded 2021 and it took almost 1 year (Jan 2022) to raise first external round
Investors
Interested in researching Protai?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Protai
